Sai Life Sciences Q2 FY27 Earnings Call: Posts 23% Revenue Growth, Lands Two Strategic Pharma Deals (SAILIFE)

Sai Life Sciences Ltd held its Q2 FY27 earnings call on November 05, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Strong Top-Line, Margin Trajectory Intact

• 23% YoY revenue growth in Q2 FY 2026-2027 — CDMO up 20% and CRO up 28%; H1 FY 2026-2027 overall revenue growth stood at 17% YoY.
• 28% EBITDA margin in Q2 FY 2026-2027 — in line with the YoY margin trajectory; H1 FY 2026-2027 EBITDA margin also stood at 28%.
• CRO 38% / CDMO 62% revenue mix — split of H1 FY 2026-2027 revenue; CRO has now posted strong growth for the last 8 quarters through Q2 FY 2026-2027.
• Management expects H2 FY 2026-2027 to be stronger than H1 — citing good visibility, but declined to quantify; analyst Rahul Jivani noted the typical historical H1:H2 split has been 40:60 (analyst-cited pattern, not reaffirmed as guidance).
• Headcount ~4,400 at end-September 2026 — management does not break down headcount between CRO and CDMO but pointed to prior disclosed figures as evidence of people-led growth.

Integrated Engagements Move From Concept to Conversion

• Two large pharma relationships converted to strategic engagements — the first end-to-end integrated collaboration customer (a top-tier pharma company announced previously) is expected to become fully functional in Q3 FY 2026-2027; no revenue potential was quantified ("We've never done and never will," per CEO Krishna Kanumuri).
• Early revenue could begin in any vertical — development or manufacturing, depending on each customer's need; management framed developments as "early signs" validating direction of travel, not committed outcomes, with "no guarantees" on pace or size.
• Industry context on the strategic-partner universe — management said almost every large pharma is evaluating some level of strategic engagement in India, driven by the need for a China-independent supply chain, with each large pharma thinking about "one or two" Indian strategic partners; no pharma company is currently seeking full end-to-end integration with a single Indian CDMO.
• Peer benchmark cited — CFO Shiva Chitto referenced integrated CRDMOs WuXi and Pharmaron as having a significantly longer trend of consistent growth built around strategic relationships.
• Growth affirmation without quantification — management affirmed there will be growth in the integrated-partnerships portion of the business over FY 2027-2028 and FY 2028-2029.
• Customer concentration outlook — largest customer was ~12% of revenue as announced at the end of last year; management believes over the next 2-3 years (through FY 2029-2030) the top 10 customers will "come back in a different order," with 2 new customers already onboarded and more planned.

Bidar Ready, 225 KL Delayed, Capex Plan on Track

• Rs.621 Cr capex incurred in H1 FY 2026-2027 — of which Rs.358 Cr in Q2 FY 2026-2027; on track with the FY 2026-2027 plan of Rs.1,100-1,300 crores.
• ~220 KL expanded small molecule capacity at Bidar is ready — final quality trials underway ahead of commercial batches; expected to be revenue accretive in FY 2026-2027.
• Second 225 KL block delayed to Q3 FY 2027-2028 — shifted from Q4 FY 2027 (i.e., Q1 FY 2027-2028); CFO attributed the shift to prioritizing other capacity/capability needed by a couple of large pharma customers; management does not expect the change to affect FY 2027-2028 revenue commitments.
• Q2 FY 2026-2027 plant utilization at 67% — CFO noted a CDMO plant is considered fully utilized at around 70-75% utilization; no ramp-up or break-even timeline was quantified.
• No firm customer commitments behind new capacity — capacity decisions are taken 24-36 months in advance on ROI and customer potential; capacity is built on "potentials and possibilities" since customers will move products to another supplier if capacity is not ready.
• Strong capex cycle expected over the next couple of years — guidance first given in the Q1 FY 2026-2027 Q&A remains intact; no 3-4 year capex guidance yet (period unspecified). CFO: "we will not stop the business of capex," and if funding needs arise the company will "do both" — return to the market and take on leverage; leverage currently "fairly comfortable."
• Greenfield site capacity not yet quantified — the land parcel is bigger than the current Beedur site and will support multiple modalities; more detail to be shared as planning progresses.

Late-Phase Bucket Steady; Commercial Portfolio Edges Up

• 14 programs in late phase and 34 at commercial stage — as of Q2 FY 2026-2027, per CFO Shiva Chitto, directing analysts to the investor deck.
• Late-phase (Phase 3 / registration / pre-registration) bucket unchanged at 14 — it was already 14 in Q1 FY 2026-2027 (June); one molecule moved out and one came in during Q2. The 11 figure in the Q1 presentation was as of March 31, 2026 (FY 2025-2026 year-end), with 3 molecules added on the Q1 call.
• Commercial count at 34 after a Q1 typo correction — the 34 shown in the Q1 FY 2026-2027 deck was a typo (actual was 33 after one molecule churned); in Q2 the count stands at 34 based on a product moving from late phase to commercial.
• 1 molecule added to the commercial portfolio in Q2 FY 2026-2027 — molecules taken from discovery to market remain at 5; CFO declined to disclose supplier position or wallet share, noting the model is built on integrating CRO and CDMO and following the molecule, with tactical second-supplier opportunities.
• Integrated discovery push into large pharma — management is making an ongoing effort, backed by automation investments, to enter at least 1-2 large pharma accounts via integrated discovery offerings (chemistry with GMPK and/or biology) (period unspecified); two integrated discovery programs commenced in Q2 FY 2026-2027, currently small but viewed as validation of the model.

Peptides and ADCs Build Out; AI Seen as Net Positive

• First peptide development lab commissioned — as flagged on the previous call; additional labs expected within the next few months of FY 2026-2027; Telangana peptide plant groundbreaking expected in Q4 FY 2026-2027 (January-February) once the master plan is complete.
• No manufacturing capacity for new modalities yet — oligonucleotides, lipids, and peptides beyond GLP-1 remain at discovery or early process development scale as of Q2 FY 2026-2027; CEO noted manufacturing technology is "changing dramatically" and existing GLP-1 capacity is based on technology "not sustainable long run."
• ADC/bioconjugation discovery active — discovery labs operational, class six containment development labs coming on board very soon, CMT labs almost online in FY 2026-2027; management is still evaluating next steps for larger moves on the ADC side.
• Gradual modality migration over the next 2-3 years — CEO described clients starting with small molecules, then entering ADCs beginning with linkers and payloads before moving to conjugation, with development work moving into high-potency areas and peptides.
• AI impact on discovery seen as limited — CEO said molecules must still be made and tested regardless of design; pharma contacts told management AI would probably lead to more molecules rather than reduced budgets, and no downward shift has been seen in pharma external outsourcing budgets (third-party context; proof of AI effectiveness in discovery not yet out). AI tools for process optimization were framed as making Indian CDMOs more competitive.
• Biotech funding in a mid-cycle phase — CEO said biotech funding will come back after the current phase of selling late-stage assets; CFO added that IPO and acquisition activity in FY 2026-2027 is giving VCs confidence that exits exist, with early green shoots visible.

Cost Headwinds Managed; Long-Term Goals Reaffirmed

• Middle East situation raising chemical/solvent costs — a modest increase in raw material costs; supply chain teams are ensuring availability, and the company is working with customers to recover incremental costs, with the impact expected to be managed through recovery mechanisms over time.
• Regulatory backdrop cited as industry context, not guidance — a proposed rule under the Coins Act in the US seeks additional restrictions on certain US investments involving Chinese biotechnology companies, while China's Ministry of Commerce and Ministry of Science and Technology have proposed additional controls on selected technology exports including biomedicine; management cautioned the eventual impact "remains to be seen" but said these reinforce geographic diversification and resilient supply-chain partnerships.
• Growth bottlenecks acknowledged — CFO said pharma relationships take a long time with no shortcuts and talent is one challenge, with measures in place to manage constraints; CEO stressed the company "will not rush just to add revenue" and must balance growth with service quality and customer satisfaction.
• Customer-relationship moat defended — responding to analyst Sajal Kapoor's point on >90% of revenues from returning customers and ~20% annual staff turnover, CFO said relationships are built at the senior level where turnover is "extremely low"; CEO added no pharma company would move business "for a single individual."
• Long-term confidence reaffirmed — management remains confident of achieving its stated long-term growth and EBITDA predictions; CFO closed by saying longer-term goals and stated positions remain intact, with focus on balancing investments with execution and commissioning capacities to required quality standards.